SWP
ITCI

Stratos Wealth Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Stratos Wealth Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-33
Closed -$1K – 2665
2018
Q1 		$1K Buy
+33
New +$643 ﹤0.01% 3052

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Stratos Wealth Partners's ITCI Position: Q2 2018 in Review

Stratos Wealth Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2018, closing a stake of 33 shares — an estimated $1K sold.

Stratos Wealth Partners first reported a position in ITCI in Q1 2018 and held it in 1 quarter. The position peaked at $1K in Q1 2018. 131 funds tracked by Wall St. Rank hold ITCI as of Q2 2018.

  • Stratos Wealth Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 33 Intra-Cellular Therapies Inc. shares in Q2 2018, an estimated $1K.
  • Stratos Wealth Partners first reported a position in Intra-Cellular Therapies Inc. in Q1 2018 and held it in 1 quarter.
  • Stratos Wealth Partners's Intra-Cellular Therapies Inc. position peaked at $1K in Q1 2018.
  • 131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2018.

Based on Stratos Wealth Partners's 13F filing for Q2 2018, filed 13 Aug 2018.